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Background: HIV differentiated service delivery (DSD) models
are scaling up in resource-limited settings for stable patients; less is
known about DSD outcomes for patients with viremia. We evaluated
the effect on viral suppression (VS) of a streamlined care DSD
model implemented in the SEARCH randomized universal test and
treat trial in rural Uganda and Kenya (NCT:01864603).
Methods: We included HIV-infected adults at baseline (2013) who
were country guideline antiretroviral therapy (ART) eligible (prior
ART experience or CD4 # 350) with $1 HIV clinic visit between
2013 and 2017 in SEARCH communities randomized to intervention
(N = 16) or control (N = 16). We assessed the effect of streamlined
care in intervention community clinics (patient-centered care,
increased appointment spacing, improved clinic access, reminders,
and tracking) on VS at 3 years. Analysis was stratified by the
baseline care status: ART-experienced with viremia, ART-naïve
with CD4 # 350, or ART-experienced with VS.
Results: Among 6190 ART-eligible persons in care, year 3 VS was
90% in intervention and 87% in control arms (RR 1.03, 95% CI:
1.01 to 1.06). Among ART-experienced persons with baseline
viremia, streamlined care was associated with higher VS (67% vs
47%, RR 1.41, 95% CI: 1.05 to 1.91). Among ART-naïve persons,
VS was not significantly higher with streamlined care (83% vs 79%,
RR 1.05, 95% CI: 0.95 to 1.16). Among ART-experienced persons
with baseline VS, nearly all remained virally suppressed in both arms
(97% vs 95%, RR 1.01, 95% CI: 1.00 to 1.03).
Conclusions: Streamlined care was associated with higher viral
suppression among ART-experienced patients with viremia in this
randomized evaluation of ART-eligible patients who were in care
after universal HIV testing.
Key Words: HIV, universal test and treat, differentiated service
delivery, differentiated care, viral suppression, East Africa
(J Acquir Immune Defic Syndr 2020;85:571–578)
INTRODUCTION
Of the 37.9 million people living with HIV globally,
over half live in eastern and southern Africa.1 This region has
made significant progress toward UNAIDS 90-90-90 targets
over the past several years; however, 42% of people living
with HIV in the region remain virally unsuppressed as of
2018.1 To close this gap, interventions are needed across the
HIV care cascade to diagnose the 15% who remain unaware
of their HIV status, initiate antiretroviral therapy (ART) in the
21% of those diagnosed who are not yet on treatment, and
achieve viral suppression (VS) among the 13% on ART but
not yet suppressed.1
Universal test and treat (UTT) is a promising and
feasible strategy for achieving HIV epidemic control through
population-level HIV testing and rapid initiation of ART,
with results from several recent UTT trials exceeding 90-90-
90 targets.2 However, as we move toward universal ART
coverage, health systems must adapt to accommodate greater
numbers of patients while simultaneously addressing the
needs of patients who do not achieve VS despite routine
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ART care. Differentiated service delivery (DSD) models were
developed to address this challenge by moving away from a
“one size fits all” model to one focused on adapting HIV care
to individual patient need.3 To date, DSD models have
predominantly focused on deintensifying HIV care for stable,
virally suppressed patients to reduce burden on the health
system and decrease barriers to long-term retention in care for
these individuals.4–6 DSD interventions to specifically
address the needs of individuals with ongoing viremia despite
ART have been less successful.3,4
Although poor adherence is the most common reason
for an unsuppressed viral load among patients on ART, a
recent trial of an adherence counseling intervention was
unsuccessful in improving VS in this population.7 Switch to
second line therapy among patients with viral failure when
adherence interventions are unsuccessful is also important for
preventing morbidity and mortality, although delays in
appropriate switch are common.8–10 Better DSD interventions
are needed for viremic patients to most appropriately target
services to improve population-level VS. Integrated DSD
models are also needed that reduce common barriers to care
for all patients and provide tailored services to viremic and
virally suppressed patients alike.
In the SEARCH study, a cluster randomized UTT trial,
all communities received comprehensive baseline HIV test-
ing; intervention communities further received enhanced
linkage to care and “streamlined care” interventions.11
Streamlined care is a DSD model designed to reduce
structural barriers, improve patient–provider relationships,
and increase patient and provider HIV-related knowledge and
skills, with the goal of improving care engagement and VS for
all patients.12 In this analysis, we sought to understand the
effect of streamlined care on VS among HIV-infected persons
who were ART eligible by country guidelines at study start in
both intervention and control SEARCH trial communities.
We evaluated the effect of streamlined care among those who
were already on ART with or without VS and those who




This analysis uses data from the SEARCH study
(NCT:01864603), a community cluster randomized con-
trolled trial in rural Kenya and Uganda conducted from
2013 to 2017 that evaluated a UTT strategy for reducing HIV
incidence and improving community health outcomes.11
SEARCH conducted baseline HIV testing in 16 intervention
and 16 control communities through community health fairs,
with health fair nonattendees receiving home visits during
which HIV testing was offered. Individuals identified as HIV
infected in both intervention and control received baseline
CD4 and viral load testing, were introduced to a clinic staff
member in person or by phone, were scheduled for an
appointment at the local HIV clinic within 1 week or within
2 days if pregnant or with CD4,200/mL, and were given a 1-
time transportation to facilitate linkage to care. Intervention
participants were additionally given a phone number (staffed
24 h/d) to call with questions.13 Intervention participants who
missed their initial clinic appointment received a phone call,
or a home visit if the phone call was unsuccessful, to
reschedule their appointment.14 SEARCH clinical staff were
present at the primary government-run HIV clinics within
both intervention and control communities.
ART Eligibility
In both Kenya and Uganda at study baseline (2013),
persons were eligible for ART initiation if they met any of the
following conditions: (1) were diagnosed with a WHO stage 3
or 4 condition, (2) CD4 count was #350/mL, or (3) CD4 was
.350, and the patient had active tuberculosis, hepatitis B
virus co-infection, HIV-associated nephropathy, or preg-
nancy.15,16 ART eligibility expanded to include individuals
with CD4 #500 in all communities by 2014.17,18
Study Population
For this analysis, we included adolescents and adults
(age $15 years) in all of the 32 SEARCH communities who
were: (1) HIV infected at study baseline, (2) had at least 1
postbaseline HIV care visit at a SEARCH-supported health
facility, and (3) were ART eligible based on either previous
ART experience or CD4 count of #350 at study baseline.
Analyses were conducted in both the overall study population
and in subgroups of patients defined by the baseline care
status: ART experienced with baseline viremia, ART-naïve
with CD4 #350, or ART experienced with baseline VS. For
purposes of this analysis, “ART experience” is defined as a
baseline patient report or medical record indication of any
previous ART, and “ART-naïve” is defined as both baseline
patient report that they had not previously been on ART and
no indication of previous ART in the medical record. Patients
with a suppressed HIV viral load at baseline were considered
ART experienced. The goal of this analysis was to isolate the
effect of streamlined care from other interventions in
SEARCH by restricting the study population to ART-
eligible patients who linked to care and to understand the
effects of streamlined care on different groups of treatment
experienced and treatment naïve patients.
Streamlined Care Intervention
(Differentiated Service Delivery Model)
Details of the SEARCH streamlined care model that
was implemented in intervention communities have been
published previously.12 The primary objectives of streamlined
care were to: (1) reduce structural barriers to care, (2) improve
relationships between patients and the clinic, and (3) enhance
patient and clinician knowledge of HIV and ART.
Streamlined care sought to address structural barriers,
including long wait times, fixed clinic hours, lack of efficient
appointment reminder and tracing mechanisms, and trans-
portation cost and inconvenience associated with accessing
care. A nurse-driven triage system was implemented to
efficiently tailor clinic visits to what patients needed, with
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the goal of reducing wait times. Scheduled visit intervals and
ART pick-up were lengthened to every 3 months for stable
patients to decrease wait times through reduced patient
volume and increase convenience associated with less
frequent clinic visits. Streamlined care also introduced
integrated multidisease care for hypertension and diabetes,
to reduce opportunity cost associated with accessing non-
integrated care for these comorbidities. Streamlined care
included appointment reminders and phone access for
health-related questions or appointment rescheduling. Patients
unable to attend clinic during normal operating hours were
accommodated with off-hours clinic access. Finally, for
patients who missed a clinic visit, re-engagement efforts of
increasing intensity were offered, including an initial phone
call followed by physical tracing and facilitated transportation
to return to care.
Streamlined care facilitated improved relationships with
patients through provider and staff training on providing
friendly care, including didactic lectures and role-playing
exercises. Relationships with patients were also facilitated
through improved communication with the clinic by appoint-
ment reminders, phone access to clinic, flexible clinic hours,
and enhanced patient tracking after missed appointments.
Finally, streamlined care aimed to improve patient and
clinician knowledge of HIV and ART through improved viral
load counseling. HIV viral load was measured 6 months after
ART initiation, then annually thereafter. Case-based training
was conducted with providers to enhance provider knowledge
and to improve providers’ ability to communicate viral load
results to patients. Phone access to clinic was also designed to
answer patient questions that arose between clinic visits,
further improving patient knowledge about HIV and ART.
Standard of Care
In control communities, standard HIV care was pro-
vided according to contemporary country ART guidelines.
Recommended monitoring frequency included clinical eval-
uation on a monthly basis for the first 6 months after ART
initiation, followed by return visits for ART refill and clinical
evaluation every 1–2 months thereafter. Optional HIV viral
load testing was conducted every 12 months or when viral
failure was suspected.
Outcomes
Our primary outcome was VS (,500 copies/mL) 3
years after study baseline, among those with a measured HIV
viral load. Extensive tracing efforts were made in both
intervention and control communities to ascertain the vital
status and measure HIV viral loads in all SEARCH partic-
ipants at year 3. We conducted sensitivity analysis with a
combined failure outcome of death or year 3 viral load
$500 copies/mL.
We also evaluated 2 measures of care engagement: time
in care and missed visits by 90 days. To calculate these
measures, we recorded all clinic visits for ART pick up and
scheduled return dates. The follow-up time began at the
patient’s initial postbaseline visit and concluded at study end,
transfer to another clinic, relocation out of the study area, or
death. Patients were considered out of care during the period
between a missed appointment and their return; they were
considered in care otherwise. We then calculated the pro-
portion of follow-up time that patients were in care (“time in
care”)19 and the occurrence of a missed visit without return to
care for $90 days.
We also report second-line ART switch among patients
who were on first line therapy and viremic at study baseline.
First-line therapy was defined as ART with a non-nucleoside
reverse transcriptase inhibitor (NNRTI) and 2 nucleoside
reverse transcriptase inhibitors (NRTIs). Second-line ART
included a boosted protease inhibitor (PI, eg, lopinavir/
ritonavir or atazanavir/ritonavir).
Analysis
We describe baseline demographic characteristics
among participants meeting inclusion criteria for this analysis
in both intervention and control. We also describe imple-
mentation of streamlined care visit interval spacing by
reporting the scheduled visit interval, defined as the time
between a visit and the patient’s scheduled return date.
We compared VS in intervention and control commu-
nities using a 2-staged approach, accounting for clustering
and the matched-pair design.20 We first calculated the
percentage of participants in each community with a sup-
pressed viral load. Next, we compared percent VS between
intervention and control communities using community-level
targeted maximum likelihood estimation.21
Secondary endpoints were assessed using a similar 2-
staged approach. We estimated the proportion of total “time
in care” for each study participant and then calculated the
mean “time in care” for each community. For each commu-
nity, we used Kaplan–Meier to estimate the cumulative
incidence of missed visits by $90 days with censoring at
transfer to another facility, permanent move out of the com-
munity, or death; point estimates were reported at 30 months
of follow-up. Finally, we estimated the community-level
proportion of participants with baseline ART experience
and viremia who switched to second-line ART.
In an additional exploratory analysis, we compared year
3 VS between intervention and control communities, stratified
by switch to second-line ART among participants with
baseline ART-experience and viremia; these analyses were
conducted with an individual-level targeted maximum likeli-
hood estimation accounting for clustering by community.
RESULTS
Study Population
Baseline comprehensive HIV testing identified 7951
HIV-infected adults in intervention communities and 6981
HIV-infected adults in control communities (Fig. 1). Among
those identified as HIV-infected on baseline testing, 5166
(65%) intervention participants and 4037 (58%) control
participants linked to HIV care at a study-supported clinic
within their community. Overall, 87% of intervention
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participants and 66% of control participants had any record of
linking to care after baseline HIV-testing, including those
who linked to care outside the study area and were thus not
included in this analysis. Among those linked to care at a
SEARCH-supported clinic, 6190 were baseline ART-eligible
according to country guidelines and included in this analysis:
3394 in intervention communities (85% treatment-
experienced and 15% treatment-naïve with CD4 # 350)
and 2796 in control communities (87% treatment-experienced
and 13% treatment-naïve with CD4 # 350).
There were no significant differences between inter-
vention and control community members who were HIV+ at
baseline, ART-eligible, and linked to care (Table 1). The
median age (IQR) was 37 years (30–45), and 34% were men.
There was a slightly longer median time between initial
community health campaign and the first or next clinic visit
for intervention participants than control (51 vs 42 days). A
lower proportion of intervention participants worked in “high-
risk” informal occupations than control (10% vs 19%), and a
slightly greater proportion of intervention participants were
youth aged 15–24 (10% vs 8%).
Scheduled visit intervals were longer in the streamlined
care arm than the control arm across all baseline care status
groups and lengthened in the streamlined care arm over the
duration of the study (Table 2).
Viral Suppression
In the overall study population for this analysis, year 3
VS was slightly higher in the streamlined care arm than
control (90% vs 87%, respectively; relative risk (RR) 1.03,
95% confidence interval (CI) 1.01 to 1.06). Effects on VS
were similar among men (87% vs 85%, RR 1.05, 95% CI:
0.99 to 1.05) and women (91% vs 88%, RR 1.04, 1.01 to
1.07). Year 3 viral load was measured in 82% of participants
who were alive at the end of the study, with similar
measurement in intervention and control (see Table 1,
Supplemental Digital Content, http://links.lww.com/QAI/
B544).
In stratified analysis by the baseline care status (Table
3, see Table 2, Supplemental Digital Content, http://links.
lww.com/QAI/B544), individuals who were ART-
experienced with baseline viremia had substantially higher
year 3 VS in the streamlined care arm compared with standard
care (67% vs 47%, RR 1.41, 95% CI: 1.05 to 1.91), with
similar effects for both men and women. Among ART-naïve
persons with CD4#350, year 3 VS was similar in streamlined
care and control (83% vs 79%, RR 1.05, 95% CI: 0.95 to
1.16). Among ART-experienced persons with baseline VS,
both arms maintained high levels of VS at year 3 (97% vs
95%, RR 1.01, 95% CI: 1.00 to 1.03).
Sensitivity analyses using a composite failure outcome
of viremia or death by year 3 yielded similar findings for the
overall study population and each baseline care group (see
Table 3, Supplemental Digital Content, http://links.lww.com/
QAI/B544). Additional sensitivity analysis among the ART-
naïve group to include those with baseline CD4 count #500
showed slightly higher year 3 VS in streamlined care
compared with control (86% vs 80%, RR 1.07, 95% CI:
1.00 to 1.16; see Table 4 Supplemental Digital Content,
http://links.lww.com/QAI/B544).
Care Engagement
Streamlined care was associated with more time in care
and less frequent 90-day missed visits across all baseline care
status groups (Table 3). Among ART-experienced patients
with baseline viremia, “time in care” was higher in the
streamlined care arm (RR 1.11, 95% CI: 1.02 to 1.19),
corresponding to an average increase in 4 weeks per year of
additional time adherent to appointment schedules. Among
ART-experienced patients with baseline viremia, streamlined
care was also associated with a 25% reduction in missed visits
by $90 days (RR 0.75, 95% CI: 0.58 to 0.98).
Second-Line ART Switch
Among ART-experienced patients with baseline vire-
mia, 93% were on first-line, NNRTI-based ART and 5% were
on second-line, PI-based ART at baseline. Among those on
first-line ART at baseline, 17% of intervention participants
and 10% of control participants switched to second-line
therapy by year 3 (RR 1.64, 95% CI: 0.81 to 3.32). Among
FIGURE 1. Study flow diagram.
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those who remained on first-line ART, year 3 VS was 65% in
intervention and 46% in control (RR 1.43, 95% CI: 1.09 to
1.87). Among those who switched to second-line ART, year 3
VS was 78% in intervention and 58% in control (RR 1.35,
95% CI: 0.83 to 2.21) (Table 4).
DISCUSSION
Our study demonstrates that a multicomponent “stream-
lined care” intervention can achieve higher VS for ART-
experienced patients with viremia than standard care while
improving care efficiency for all patients. In particular, ART-
experienced individuals with baseline viremia had a 20%
absolute increase in VS after 3 years in streamlined care
compared with standard care. Individuals who were virally
suppressed at study baseline maintained similar, very high
levels of VS in both intervention and control communities,
but with less frequent clinic visits in streamlined care.
Streamlined care also achieved similar levels of VS as
standard of care among individuals newly starting ART,
TABLE 1. Baseline Characteristics by the Study Arm
Intervention (n = 3394) Control (n = 2796)
n or Median % or IQR n or Median % or IQR
Region, n (%)
Eastern Uganda 422 12% 302 11%
Kenya 2308 68% 1938 69%
Western Uganda 664 20% 556 20%
Male sex, n (%) 1130 33% 948 34%
Age category, n (%)
15–24 yrs 327 10% 211 8%
25–49 yrs 2411 71% 2067 74%
$50 yrs 656 19% 518 19%
Marital status, n (%)
Single 198 6% 134 5%
Married 2267 68% 1875 67%
Widowed/Divorced/Separated 879 26% 773 28%
Occupation*, n (%)
Formal sector 165 5% 113 4%
High-risk informal 327 10% 523 19%
Low-risk informal 2505 74% 1801 64%
No job or disabled 173 5% 193 7%
Other or missing 224 7% 166 6%
Baseline pregnancy, n (%, of women) 114 5% 99 5%
Time since ART initiation (yr), median (IQR) 3.2 2.6–3.7 3.5 3.1–3.8
Time from baseline community health fair to next clinic
visit (d), median (IQR)†
51 24–93 42 20–103
Baseline CD4, n (%)
,200 372 11% 304 11%
200–350 828 24% 606 22%
351–500 586 17% 499 18%
.500 1262 37% 1120 40%
Missing 346 10% 267 10%
Comorbid conditions, n (%)
Hypertension 278 9% 222 9%
Diabetes 40 1% 39 2%
Baseline care status, n (%)
ART-experienced, baseline viremia‡ 330 10% 238 9%
ART-experienced, baseline suppression§ 1646 48% 1311 47%
ART-experienced, baseline VL missing 904 27% 896 32%
ART-naïve, CD4 # 350 514 15% 351 13%
*A formal sector occupation was defined as a teacher, student, government worker, military worker, health worker, or factory worker. A high-risk informal sector occupation was
defined as a fishmonger, fisher, bar owner, bar worker, transportation worker, or tourism worker. A low-risk informal sector occupation was defined as a farmer, shopkeeper, market
vendor, hotel worker, homemaker, household worker, construction worker, or miner.
†A community health fair was conducted at baseline in all communities with nonattendees tracked in the community for baseline HIV testing. The time calculated from date of
community health fair to the first/next clinic visit.
‡Viral load $ 500 copies/mL.
§Viral load , 500 copies/mL.
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despite enhanced linkage efforts in intervention communities
that may have brought more patients to care who had pre-
existing barriers to care engagement.14 Sensitivity analyses
further suggest that VS may have been higher among ART-
naïve individuals in the streamlined care group when
including those with baseline CD4,500, the threshold for
initiating ART in control communities within 0–11 months
after study baseline after country-level ART guideline
changes.17,18
Our findings suggest that streamlined care likely
improved VS among ART-experienced patients with baseline
viremia primarily through reduction in barriers to care
engagement and improved adherence support. We observed
both increased time in care and reduction in 90-day gaps in
care, suggesting that streamlined care improved care engage-
ment in this population. Although streamlined care was
associated with a small, nonsignificant increase in switch to
second-line ART, improvements in VS were similar regard-
less of whether or not patients switched to second-line ART.
This finding suggests that the quality of care delivered may
have been the most important factor in achieving VS, even
among patients who did switch to second-line therapy.
Streamlined care was designed to improve care access
and engagement through 3 primary mechanisms, namely (1)
reduction of structural barriers to care, (2) improvements in
relationships between patients and the clinic, and (3)
enhanced patient and clinician knowledge of HIV and
ART.12 First, structural barriers such as transportation costs,
wait times, and opportunity costs can reduce retention in care
and VS.22 We have previously demonstrated that streamlined
care reduced the average total time for a clinic visit from
155 minutes to 73 minutes, an “undifferentiated” intervention
that reduces barriers for all patients.23 Here, we show that
streamlined care also reduced the frequency that patients
needed to return to the clinic for medication pickup and
provider visits, including for patients with ART experience
and baseline viremia, further reducing structural barriers
to care.
Second, poor relationships with clinicians have been
shown to reduce retention in care and discourage patients
from returning to care after a lapse.24,25 Furthermore, surveys
of patient preference suggest that patients would be willing to
travel further, wait longer, and pick up medications more
frequently to receive care from a “nice” provider as opposed
to a “rude” provider, suggesting that provider attitude is
highly prioritized by patients.26 Streamlined care aimed to
directly improve patient–staff relationships through trainings
to practice and encourage providers and staff to provide



















Visit interval, median days (IQR)
Year 1 50 (37–62) 39 (32–50) 42 (31–50) 36 (28–46) 58 (47–70) 47 (36–56)
Year 2 63 (43–79) 43 (31–54) 70 (51–84) 50 (36–58) 75 (63–84) 51 (40–58)
Year 3 65 (42–83) 46 (33–57) 70 (55–84) 51 (38–58) 78 (64–84) 56 (43–62)
*Viral load $ 500 copies/mL.
†Viral load , 500 copies/mL.
TABLE 3. Effect of Streamlined Care on Engagement and Retention in Care



















VS at year 3† 67% 47% 1.41 (1.05 to 1.91) 83% 79% 1.05 (0.95 to 1.16) 97% 95% 1.01 (1.00 to 1.03)
Men 66% 55% 1.21 (0.89 to 1.65) 78% 72% 1.09 (0.91 to 1.30) 96% 95% 1.01 (0.98 to 1.03)
Women 66% 44% 1.52 (1.01 to 2.28) 88% 86% 1.03 (0.93 to 1.14) 97% 96% 1.01 (1.00 to 1.03)
Time in care (TIC) 81% 73% 1.11 (1.02 to 1.19) 74% 67% 1.10 (1.03 to 1.17) 86% 81% 1.07 (1.01 to 1.13)
Men 81% 71% 1.15 (1.01 to 1.30) 72% 66% 1.10 (0.98 to 1.22) 86% 83% 1.04 (1.00 to 1.09)




30% 40% 0.75 (0.58 to 0.98) 36% 46% 0.79 (0.65 to 0.96) 21% 29% 0.75 (0.46 to 1.20)
Men 34% 39% 0.87 (0.57 to 1.33) 37% 49% 0.75 (0.55 to 1.03) 23% 24% 0.96 (0.66 to 1.38)
Women 28% 40% 0.69 (0.47 to 1.03) 35% 43% 0.81 (0.62 to 1.07) 21% 30% 0.68 (0.40 to 1.16)
*Viral load $500 copies/mL.
†Viral load ,500 copies/mL.
‡Assessed at 30 months post-baseline
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friendly, patient-centered services, and through improved
patient access to clinicians. We have previously reported
the importance of friendly services for promoting retention in
care among men within SEARCH.27
Finally, improved patient and provider knowledge, moti-
vation, and engagement are important for achieving optimal HIV
outcomes and may also improve patient–provider interac-
tions.22,28 In turn, greater patient activation may reduce stigma
and encourage patients to become advocates for others in their
community.29 Streamlined care aimed to improve knowledge and
reduce stigma by providing enhanced viral load counseling to
help patients understand the meaning of suppressed and unsup-
pressed results. Integration of HIV and noncommunicable dis-
ease care may have also contributed to stigma reduction—both
for patients with and without a noncommunicable disease.30
Essentially, by broadening the services offered, clinics became
not simply “HIV clinics,” but rather “chronic care clinics.”
Cost is a key consideration for adoption of any care
intervention. Estimated costs of streamlined care are $291
per-patient per-year, similar to or lower than that of PEPFAR-
supported care elsewhere in sub-Saharan Africa.31 Some
costs, such as direct cost for ART or viral load testing, may
decrease over time; however, other costs may increase
somewhat with scale, including costs associated with broader
training and mentoring for clinicians to provide patient-
centered care.
Previous evaluations of the SEARCH streamlined care
intervention have shown high levels of retention in care and
VS, although these evaluations lacked a comparison
group.12,32 Here, we leverage the cluster randomized design
of SEARCH to isolate the effect of streamlined care on care
engagement and VS by comparing individuals who were
ART-eligible in both intervention and control at baseline and
who linked to care at a SEARCH-supported clinic. Although
the randomized design strengthens our findings, our study
may not be generalizable to all patients because we excluded
those who linked to care outside their community of residence
in order to ensure similar ascertainment of linkage to care
between arms. Further, for those who were linked, our
engagement in care measures do not account for care that
may have been accessed at another clinic during an observed
lapse in care. Nonetheless, these measures were ascertained in
the same way in both intervention and control communities,
and thus, differences in visit attendance and gaps in care are
likely to reflect true differences in clinic access and engage-
ment between study arms.
CONCLUSIONS
In conclusion, we found that a multicomponent stream-
lined care intervention increased care efficiency and main-
tained high levels of VS for virally suppressed and ART-
naïve patients, while simultaneously improving VS and care
engagement for ART-experienced patients with viremia. The
intervention components included in streamlined care are
likely to have relevance for all HIV care systems in resource-
limited settings, including those that have scaled up other
DSD models for stable patients. Beyond improving outcomes
for HIV care, streamlined care also holds promise as a
platform for low-barrier multidisease care that may further
reduce HIV-associated stigma and barriers to addressing
comorbid health conditions.
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